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4 Abstract 
The human immune system has developed over the course of millennia from 
the simple innate-type of immune system of simple life forms into a complex 
system comprising the innate and adaptive arms. The adaptive arm of the 
immune system is cell-dominated in its actions, while the innate arm consists 
mostly of phagocytic cells and proteins, including many enzymes. Borrelia 
burgdorferi, the causative agent of Lyme disease (borreliosis), which is a 
potentially persistent complex multi-system disorder, is an example of a 
successful human pathogen. It is capable of bypassing the immune defense 
mechanisms of the human body. The complement system is in the first line of 
this defense, and thus, for a microbe to be a pathogen and infectious to 
humans, it must first bypass this system.  
Lyme disease is caused by three genospecies that all belong to Borrelia 
burgdorferi sensu lato (s. l.): B. burgdorferi sensu stricto (s. s.), Borrelia afzelii
and Borrelia garinii, which share only about 80% of common genetic material. 
The most prevalent clinical manifestations of borreliosis vary. B. burgdorferi s. 
s. is mostly arthrotropic, B. afzelii dermotropic, and B. garinii neurotropic. The 
aim of this study was to characterize the complement evasion features 
common and unique to each of these strains. More specifically, we wanted to 
find out, a) by which mechanism Borrelia burgdorferi bypasses the 
complement system, and b) which surface molecules are associated with this 
mechanism.  
It was found that serum resistant B. burgdorferi strains bound factor H (FH), 
an inhibitor of the alternative pathway of complement from their hosts and that 
this ability correlated with the ability to resist serum-mediated lysis of the 
bacteria. FH binding promotes C3b inactivation; it prevents C3/C5 activation 
and membrane attack complex (MAC) formation. A family of surface 
expressed lipoproteins, the outer surface protein E (OspE)–family was found 
to be used by B. burgdorferi to bind FH. Individual strains expressed multiple 
OspE-proteins encoded by circular plasmids. The sequences of OspE-
proteins from B. garinii vs. those of B. afzelii and B. burgdorferi s. s. were 
found to vary. These variations may account for the differences in the serum 
sensitivities of these strains. In addition to OspE, a second FH-binding 
protein, approximately 35 kDa in molecular weight, was also found.  
The OspE-protein family members were found to constitute a repertoire of 
FH-binding proteins, whose expression depends on signals from the external 
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environment. The expression of OspE-proteins becomes upregulated at 
37°C, which is a key feature making them available when the spirochetes are 
subjected to the immune attacks of warm-blooded mammals. OspE proteins 
were thus found to constitute a family of mobile virulence factors, whose 
expression becomes induced in the host. The binding sites on FH and OspE 
were found to be located at the C-terminus of FH and at the N- and C-termini 
of OspE. The essential amino acid residues of OspE in the interaction were 
found to be lysines.  
FH binding apparently has an essential role in the ecology of the enzootic 
cycle (existence in different hosts) of B. burgdorferi. B. burgdorferi is able to 
infect a number of different animal hosts and bind FH from the host 
environment. There are typically several copies of genes encoding OspE-
family proteins in a single bacterial strain, suggesting that their function may 
be related to different stages of the enzootic cycle. FH binding, therefore, has 
an essential role in the adaptation of the spirochete to the immune systems of 
the various hosts.  
In conclusion, a new family of Borrelia burgdorferi virulence factors, the OspE-
protein family, is described in this work. These factors are surface expressed 
and contain crucial FH-binding determinants.  OspE-proteins are tentatively 
important in the successful persistence of the spirochete in the human body. 
This new information is of potential use in development of a new multi-strain 
vaccine effective against all three Lyme disease -causing genospecies.  
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5 Introduction 
5.1 The human immune system – adaptive and innate arms 
The most important first lines of defense of the human body against invading 
microorganisms are physical barriers, such as skin, and mucous membranes. 
After pathogenic microbes penetrate these barriers, the immune system steps 
in. It is customary to divide the immune system into two systems, a 
nonspecific system, which attacks foreign surfaces and a specific system, 
which develops diversity, specificity and memory of how to combat the 
specific microorganism. These are also known as the innate immune system 
and the adaptive immune system, respectively. 
In addition to the aspect of recognition, these terms also encompass the 
aspect of evolutionary origin. The innate immune system is the more simple 
one, and more archaic in evolutionary origin (5). The adaptive immune 
system, which requires the presence of specialized cells and is only present 
in multicellular organisms, is a later development. 
The complement (C) system functions as a cascade of binding interactions 
and enzymatic events, which help in the processing of foreign material. The 
lectin (LP) and alternative pathways (AP) of complement (see Fig. 1) are 
essential components of the innate immune system. The classical pathway 
(CP) functions as a component of both innate and adaptive parts of the 
immune system.  
5.2  Functions of complement as part of the human immune 
system 
In the course of evolution the complement system has developed from a 
simple protein cascade of single celled organisms into a network of 
recognition events, interactions and enzymatic reactions. The complement 
system is one of the most versatile parts of the immune system. Once the 
mechanical barriers to infection, namely the skin and mucous membranes, 
are disrupted it is the first line of defense against previously unencountered as 
well as familiar microbes. The complement system is usually divided into the 
alternative, classical and lectin pathways (6). The alternative pathway is 
activated by foreign surfaces and by autoamplification it coats the surfaces of 
invading bacteria with proteins, which enable their opsonophagocytosis by 
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neutrophils and other phagocytosing cells. The lectin pathway is also 
activated by foreign surfaces, but more specifically it recognizes mannose or 
N-acetylglucosamine-containing carbohydrates, relatively common molecules 
on bacterial surfaces. The classical pathway is usually seen as part of the 
adaptive immune system, because it is activated by antibodies recognizing 
previously encountered microbes, but it may also be activated in the absence 
of specific antibodies e.g. by bacterial lipopolysaccharides (7). The functions 
of complement include lysis, opsonization, targeting and enhancement of the 
immune system, and clearance of foreign material. 
5.2.1 DIRECT COMPLEMENT-MEDIATED LYSIS
Complement-mediated lysis of target cells is achieved by components of the 
complement system working in concert. The activation of complement leads 
to the terminal pathway (TP; Fig. 1), which ends in the terminal complement 
complex (TCC), or MAC. Formation of MAC results in water permeable 
hydrophilic pores being inserted into lipid bilayer membranes. The osmotic 
potential inside the attacked cell thereafter draws fluid inside, and the osmotic 
pressure eventually results in the rupture of the cell membranes.  
5.2.2 COMPLEMENT CLEARS DEBRIS AND OPSONIZES BACTERIA
In addition to direct attacks of the complement system against living bacterial 
cells, it has important functions in clearing debris from the host. The debris 
may be remnants of lysed bacteria or damaged or dead cells, for example. 
Complement molecules, such as C1q, C4b, C3b, and iC3b function as ligands 
for leukocyte receptors, such as complement receptor 1 (CR1) and 
complement receptor 3 (CR3). The phagocytosis of, for example, leprosy 
bacilli, is mediated by CR1 and CR3 (8). These receptors are found on 
antigen presenting cells such as macrophages, and dendritic cells, which 
phagocytose or pinocytose complement coated (i.e. opsonised) cells or 
particles.  
5.2.3 COMPLEMENT ACTIVATION GENERATES INFLAMMATION AND 
PRODUCES CHEMOATTRACTANTS
Complement-mediated inflammation is produced to a large extent by the 
release of powerful inflammatory agents C3a and C5a (see Fig. 2). These 
increase vascular permeability locally at the site of inflammation, resulting in 
the classical rubor, tumor, calor and dolor signs of inflammation. Chemotaxis 
also results to a large extent from the release of powerful chemoattractants 
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C3a and C5a, whose concentration gradient serves as a homing signal for 
leukocytes to sites of inflammation. Histamine is released from mast cells. 
C5a, and to a lesser extent also C3a, mediates anaphylaxis by binding to 
specific receptors C5aR, and C3aR. Deposition of MAC also induces 
inflammatory changes in tissues by activating cells via Ca++ influx to release 
leukotrienes, prostaglandins and other inflammatory mediators. 
5.2.4 NECROTIC AND APOPTOTIC CELLS ARE CLEARED BY COMPLEMENT
Necrotic or apoptotic cells are found especially in regenerating tissues. This 
debris is marked by complement for cellular processing. C3b and C4b –
molecules, which are recognized by phagocytes, opsonize immune 
complexes that form when antibodies bind to cellular debris or form other 
immune complexes. Complement recognizes key structures, such as 
chromatin, which are normally confined inside of the cells. However, C1q also 
recognizes apoptotic cells or blebs directly by binding to flip-flopped surface-
molecules. This also results in opsonization and phagocytosis. A deficiency or 
failure in this system results in systemic lupus erythematosus with 
characteristic symptoms. 
5.2.5 COMPLEMENT TARGETS AND ENHANCES SPECIFIC IMMUNE 
RESPONSES
Specific immune system enhancement is achieved when complement 
components attach to bacteria and other microorganisms to be picked up by 
cells of the immune system for antigen presentation. Such targeting is 
achieved primarily by detection of opsonised material using complement 
receptors (CR1..CR3), which are expressed on specific cells of the immune 
system. More specifically, CR1 is involved in the transport, CR2 in targeting to 
B- and dendritic cells, and CR3 in the phagocytosis of antigens. Complement 
receptor 2 is expressed by B-lymphocytes and dendritic cells and is essential 
in activating B-cells and reinforcing the immune system, especially by 
activating and enhancing adaptive immunity (9). This contributes to the 
specific targeting of the immune system.  
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Figure 1 Activation of the human complement system (1). Thick, 
discontinuous lines indicate enzymatic activity. The complement system is 
developmentally an ancient system, with the alternative and lectin pathways, 
as parts of the innate immune system, being more ancient. Their development 
dates back to the Metazoa, whereas the classical pathway, along with the 
adaptive immune system, developed in jawed invertebrates (5). 
5.3 The alternative complement pathway 
The AP is a very efficient tool of the immune system in resisting and fighting 
infection. AP function is not dependent upon previous encounters with the 
specific pathogen in question, or upon leukocytes, or other cells of the 
immune system. The liver is the major site of synthesis of all AP components, 
which are found in serum. The activation of the alternative pathway is 
triggered by default on a foreign surface and coats it with C3b. This results in 
efficient opsonization of foreign material. In the presence of phagocytosing 
cells the material is also engulfed and processed. In addition to opsonization, 
the activation proceeds to the TCC/MAC and may result in lysis of gram-
negative bacteria.  
C3 is hydrolyzed in serum. This is known as tick-over activation, which 
happens at a low rate all the time. Activated C3(H2O) binds factor B 
molecules. After cleavage of B to Bb and Ba by factor D, C3(H2O) and Bb 
together form the initial C3 convertase C3(H2O)Bb. If an activating surface is 
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present nearby, the AP feedback cycle is activated (see Fig. 2). The central 
reaction in AP activation is the cleavage of C3 to C3b by the AP convertase 
C3bBb. Because the AP is activated by default and it is efficient, it may 
become dangerous for cells of the human body if it is not tightly controlled.  
Figure 2 Activation of the Alternative Pathway of the Human Complement 
System (6). The pathway starts with tick-over activation of C3 (to the left and 
down). This refers to the autohydrolysis of an internal thiolester bond of C3 to 
create reactive groups capable of forming covalent bonds with other 
molecules.  
5.4  Complement regulation 
Regulation of the complement system is essential, because of the nonspecific 
nature of AP and LP and to some extent CP activation. In fact, if all 
complement in the human body were activated on the surfaces of our own 
cells, it would be able to destroy the entire body in a matter of hours. Fluid-
phase and surface regulatory molecules in serum and on cell membranes 
therefore, regulate complement. They can be divided into AP, CP and 
terminal pathway (TP) inhibitors and modulators. They all prevent 
unnecessary consumption of complement and protect our own tissues from 
complement attack.  
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5.4.1 C1INH 
C1-inhibitor is an inhibitor of the CP and lectin pathways inhibiting CP C1r and 
C1s, and MASP1 and MASP2 of the lectin pathway. Most important in its 
function is C1s activity regulation, but it also regulates some enzymes of the 
coagulation cascade and prevents C1r autoactivation. C1INH deficiency 
results in hereditary angioedema (HAE) (10). 
5.4.2 C4BP 
C4bp is principally a CP regulator and functions as a cofactor in the cleavage 
of C4b by FI (11). It also inactivates the CP C3-convertase C4b2a by 
promoting dissociation of C2a. C4bp can act as a cofactor also in the 
cleavage of C3b.  
5.4.3 FACTORS H AND I
Factor H (FH) is a 150 kDa AP inhibitor found in serum. It consists of 20 
FH 1
1
2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 205
FHL-1 1 2 3 4 6 75
FHR-1
FHR-2
FHR-3
FHR-4
FHR-5
1
1
1
1
1
1
2
2
2
2
2
3
3
3
3
3
4
4
4
4
6 84
5
5
5
7 95
C3b
C3b
C3b/C3c C3b/C3d
M-protein
Short consensus repeat domain (SCR), about 60 aa
Decay accelerating/cofactor activity
Heparin binding SCR
Streptococcal beta-protein and pneumococcal Hic-protein binding
C3b binding site
Figure 3 Schematic diagrams of FH-Protein Family Members FH, FHL-1 and
FHR-1. SCR alignment according to regions of homology (1). The figure
illustrates binding sites on FH for C3b, C3c, C3d and streptococcal M-protein
(2, 3). The group B streptococcal beta-protein and pneumococcal Hic-protein
binding SCRs are also indicated (4). 
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homologous short consensus repeat (SCR) domains containing 
approximately 60 aa residues each. The structure resembles a string of pearls 
(see Figs. 2 and 3). FH functions as a cofactor for factor I (FI), which cleaves 
C3b into iC3b (12). It also prevents the binding of factor B to C3b and 
accelerates the dissociation of Bb from C3 and C5 convertases.  FH-like 
protein 1 (FHL-1) and FH-related proteins 1-5 (FHR-1..FHR-5) share 
homologous SCR-domains with FH. FHL-1 shares the first 7 SCR-domains 
with FH, and thereby lacks the surface-recognition properties, but otherwise 
has most of the functional activities of FH. In contrast, the FHRs have not 
been shown to have as efficient C-regulatory functions as FH. 
5.4.4 MEMBRANE REGULATORS OF COMPLEMENT
The membrane cofactor protein (MCP; CD46) is an AP regulator and 
functions as a membrane associated cofactor in C3b cleavage. The decay-
accelerating factor (DAF; CD55) is an AP and CP regulator and accelerates 
the decay of both AP and CP C3-convertases. Protectin (CD59) is the only 
TP–regulator on cell membranes. It prevents formation of the MAC by binding 
to the C8 and C9 molecules and preventing their insertion into cell 
membranes (13). Both DAF and protectin are anchored to cell membranes via 
glycophosphoinositol (GPI) moiety. An acquired deficiency of the GPI-anchor 
occurs in paroxysmal nocturnal hemoglobinuria (PNH). Complement receptor 
1 functions as a receptor for C3b and other complement components, but also 
functions as a FI-cofactor.  
5.5  Microbial complement evasion 
Infectious microorganisms have evolved many mechanisms of bypassing 
human immune defenses, especially the complement system. This is an 
essential feature of pathogenic microorganisms. From an evolutionary aspect 
the interplay between the immune system and pathogenic bacteria could be 
described as an interface, where a long-term balance is achieved between 
fast-evolving bacteria with their ever-developing mechanisms of immune 
evasion and the ability of the immune system to control them. The occasional 
imbalance results in the generation of pathogenic microbes, which can cause 
infectious disease. Well-documented mechanisms of complement evasion 
include surface structures, like capsules, release of fluid-phase regulators 
encoded by the bacterial genome, and modulation of bacterial surface protein 
expression and binding of human complement regulators.  
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5.5.1 LPS AND CAPSULE
Oligosaccharide side-chains of lipopolysaccharides (LPS) and capsules (14) 
are carbohydrate surface structures on microbial surfaces capable of isolating 
attacks of the complement system from the lipid bilayer of the bacteria. 
Especially if these structures contain sialic acid (15), complement attack can 
be efficiently prevented. Neisseria meningitidis, for example, protects itself 
with a capsule containing sialic acid (16). 
5.5.2 MODULATION OF SURFACE PROTEIN EXPRESSION
Modulation of surface expressed antigenic determinants is a common 
mechanism in viruses evolving at a high rate, for example the Influenza-
viruses and HIV. Also some bacteria, for example B. burgdorferi, have a 
surface protein repertoire, which is capable of mutating to lead the immune 
system astray. Changes in expression have especially been found in outer 
surface protein C (OspC) (17). 
5.5.3 RELEASE OF FLUID-PHASE REGULATORS
In addition to expressing M-proteins, group A streptococci, more specifically 
the M1 serotype streptococci, have also been shown to secrete a putative 
complement control protein, streptococcal inhibitor of complement SIC (18, 
19). Some bacteria (like Pseudomonas sp. and Porphyromonas) have been 
found to release enzymes that cleave complement components (20, 21). 
5.5.4 BINDING OF HUMAN COMPLEMENT REGULATORS
Bacteria, as well as viruses and parasites, utilize the binding of human 
complement regulators for complement evasion. The Human 
Immunodeficiency virus (HIV), an enveloped retrovirus, captures surface-
associated complement control molecules, such as CD59 from the 
membranes of host cells to prevent complement attack (22-33). Some 
bacteria (e.g. group A and B streptococci and pneumococci) bind the AP-
inhibitor FH using surface proteins, such as, the M-protein (34-40), and the 
PspC-family protein Hic (41). 
5.6  Lyme disease - a tick-transmitted zoonosis 
Lyme disease (borreliosis) is a spirochetal infection transmitted by ticks of the 
Ixodes ricinus, Ixodes pacificus, Ixodes persculatus, and Ixodes scapularis
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species (42-44). The human is essentially a dead end in the enzootic cycle of 
the causative agents, the Borrelia burgdorferi s. l. Lyme disease–causing 
spirochete bacteria. The natural transmission cycle involves warm-blooded 
mammals, birds, and rodents as the natural reservoir hosts of the spirochetes. 
The most important host as well as the most important vector-tick depends on 
the geographical region. The tick maturation cycle includes the larval stage, 
nymphal stage, and adult stage of which the nymphal stage is most important 
in spirochetal transmission. There are three genospecies, which cause Lyme 
disease: B. burgdorferi s. s., B. afzelii and B. garinii. These genospecies vary 
somewhat with regard to the most prevalent clinical manifestations (see Fig. 
4) they cause.  
B. burgdorferi is transmitted from the tick mid-gut into the skin of the potential 
human host when the tick feeds on human blood. Attachment lasting over an 
average of 53 h (45) increases the likelihood of disease transmission. Borrelia
bacteria begin to change their surface antigen expression and adapt into the 
host environment, when key host-associated factors come into contact with 
the spirochetes (46-50). In the tick midgut, the spirochetes are protected from 
Figure 4 Lyme disease causing B.
burgdorferi s. l. spirochetes belong
into three distinct genospecies,
which tend to cause different
clinical manifestations in later
stage infection. 
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host complement by the tick’s saliva, which contains complement inhibitory 
substances (51).  
The first symptom of disease and the best hallmark for diagnosis is an 
enlarging bull’s-eye type of annular erythema, erythema migrans (EM), which 
has been reported to occur in 61-100 % of patients confirmed to have the 
infection (52). However, the prevalence anti-B. burgdorferi antibodies in 
endemic areas as well as selected reports suggest that EM may be more rare 
or go unnoticed more often than usually thought (53, 54). After 2-3 weeks the 
disease begins to disseminate into other organs through the bloodstream. 
Several outer surface proteins induce the formation of antibodies, which are 
characteristic for each phase of infection (55). A high level of antibodies is 
typically observed in the infection. However, the level of inflammation in 
tissues is relatively low. Also, despite the antibodies, the bacteria are often 
not cleared. 
The second stage of infection may involve various tissues and manifests as 
symptoms from the eye (ophtalmitis), nervous system (Bell’s palsy), heart 
(carditis), joints (arthritis) (56), or skin erythema.
In the third stage, the disease seems, at least in most cases, to acquire an 
immunological nature. The long-lasting high antibody response against 
spirochetal antigens has been suggested to result in the formation of 
autoantibodies against cross-reacting human structures, such as LFA-1 (57, 
58). This has been suspected to play a role in the formation of long-term 
Lyme arthritis or damage in nervous system structures, resulting in peripheral 
neuropathy (59-63). The most likely long-term outcome depends somewhat 
on the genospecies causing the infection, with acrodermatitis chronicum 
atrophicans being the most prevalent late stage outcome of B. afzelii
infection. Lyme arthritis and neuroborreliosis are similarly linked to Borrelia 
burgdorferi s. s. and B. garinii, respectively.  
5.7  Special properties of B. burgdorferi
B. burgdorferi is a 20 ?m long cork-screw-like gram-negative spirochete 
bacterium, which is very motile in phase contrast microscopy. The bacterium 
has a linear chromosome with 853 open reading frames (ORF) (64). In the B. 
burgdorferi s. s. B31 strain there are also 9 circular and 12 linear plasmids 
(The Institute for Genomic Research Comprehensive Microbial Resource; 
(65)). The outer surface of the bacterium is relatively smooth, with 43 proteins 
being expressed on the surface. Only a subset of these proteins that give the 
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spirochete a relative advantage in a particular environment, is expressed at 
any one time at the cost of energy expenditure (66, 67). The membrane 
consists of two membranes with a periplasmic space in between. Some 
surface proteins are expressed on both membranes in a dual manner (66).  
In Lyme disease pathogenesis the ability of the spirochete to invade tissues is 
essential. This ability is achieved by utilization of human matrix 
metalloproteases (MMP’s) (68, 69), and plasmin/plasminogen (70-74). By 
binding these enzymes onto its outer membrane, B. burgdorferi can penetrate 
through connective tissue similarly to leukocytes when they penetrate through 
blood vasculature. In the pathogenesis of arthritis, the use of MMPs is central 
to the observed damage in the synovium (75). 
5.8 Lyme disease prevention by vaccination 
The prevention of Lyme disease using vaccination has been the goal of 
several studies using surface proteins of B. burgdorferi. The first widely used 
vaccine was developed using the OspA surface antigen. However, reports on 
the cross-reactivity of the antigen with human leukocyte function antigen 
(LFA-1) have suggested that there may be limitations to its usefulness due to 
side-effects (58). 
5.9  Immune evasion and suppression mechanisms of B. 
burgdorferi
B. burgdorferi is among the most successful non-commensal pathogens in 
terms of immune evasion and suppression. The spirochete can persist for 
years in the human body without a marked inflammatory reaction. The 
mechanisms of persistence and survival of the spirochete in the human body 
have sparked research interest since the discovery of the bacterium. Several 
mechanisms have been reported, including surface antigen modulation, and 
upregulation of IL-10 expression. These mechanisms may be viewed as 
active and passive immune suppression/evasion mechanisms (76). 
The clinical manifestations and outcome of Lyme disease have long been 
known to vary widely between different individuals. In most cases the infection 
is cleared by the immune system with relatively few symptoms and acquisition 
of immunological memory. Humoral immunity can usually be detected 
afterwards. In various studies the prevalence of antibodies in the general 
population in endemic areas has varied from 3.4% (77) to 19.7% (78). On the 
other hand, the infection may also disseminate and cause symptoms in joints, 
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the heart, nervous system and skin. Several suggestions have been made as 
to what determines the clinical outcome. It is generally viewed that humoral 
(Th2) immunity is more important than cell-mediated immunity (Th1) in 
clearing the infection. There is evidence to suggest that, of the adaptive 
immune mechanisms, activation of B-cells is essential for both protective 
humoral immunity and disease clearance (79), and Th1-responses and 
activation of CD4+ cells may even exacerbate infection (80). Thus, T-cells are 
not central in Lyme disease immunity, although they may be important 
mediators of long-term outcomes. Apparently T-cell independent B-cell 
activation takes place in Lyme disease (80).
When causing an infection in a previously uninfected individual, the first line of 
defense, which the bacterium faces, is the alternative pathway and classical 
pathway of the complement system. The pathogenic genospecies of B. 
burgdorferi (s. s., afzelii, garinii) have been observed to differ with respect to 
their sensitivity to nonimmune serum i.e. to the complement system. In this 
study by Breitner-Ruddock et al. it was observed that sensitive strains of B. 
burgdorferi activate primarily the alternative pathway of the complement 
system, whereas the resistant strains activate the classical pathway in the 
absence of antibodies (81). Several mechanisms have been described to 
contribute to the complement evasion property of B. burgdorferi.
5.9.1 SURFACE ANTIGEN MODULATION 
Modulation of surface antigens (e.g. OspC) has been reported by Liang et al.
(17) as a mechanism for immune evasion by the spirochete. This mechanism 
reduces antibody binding to the borrelial surface. Also, specific complement 
acceptor surface proteins  have been suggested to play a role in AP evasion 
(82). Other surface antigens known to undergo genetic variation are OspE, 
DbpA, EppA, and mlp. 
5.9.2 PUTATIVE BINDING OF CD59  
Pausa et al. (83) have reported expression of a CD59-like molecule by serum 
resistant strains. Because CD59 is a terminal pathway inhibitor, the microbial 
homolog has been suggested to act by reducing terminal complement 
complex deposition by complement-activating antibody-molecules. However, 
no independent confirmation of this observation has yet been made. 
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5.9.3 INDUCTION OF IL-10 SECRETION 
Secretion of IL-10, an immunomodulatory cytokine, downregulates the cell-
mediated immune response in Lyme disease. The B. burgdorferi bacteria are 
able to induce secretion of IL-10, which results in modulation of the 
inflammatory response in early infection (76).  
5.9.4 OTHER MECHANISMS
The above do not offer a full account of the mechanisms of B. burgdorferi for 
AP evasion. Based on the characteristic features of the infection it was 
hypothesized that additional AP-specific evasion/suppression mechanisms 
must exist for B. burgdorferi to survive in the human host for extended periods 
of time. Therefore, we presented the necessary questions for further studies.  
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6 Aims 
The aims of the present study were to investigate  
a) whether the AP inhibitor FH, and/or its homologues is utilized by B. 
burgdorferi for bypassing the complement system,  
b) whether there are specific bacterial surface structures associated with 
this mechanism, 
c) what the essential structural features, motifs, or domains of these 
surface molecules are in the interaction,  
d) what homologues of these proteins exist, if any, and 
e) why B. garinii strains are more sensitive to serum, i.e. complement-
mediated killing than B. afzelii and B. burgdorferi s. s. strains. 
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7 Materials and Methods 
7.1 The B. burgdorferi genome 
The B. burgdorferi B31 genome has been entirely sequenced (64) and is 
available online at http://www.ncbi.nih.gov/Entrez/index.html. This information 
was used frequently for searching candidate proteins, looking for common 
motifs, and calculating pI-values for proteins to be used in the Biacore 
analysis. Also, sequence alignments and sequence fragmentations were 
performed using sequences from NCBI Protein Databases. The plasmid 
content of the spirochete was analyzed using the information contained in 
Entrez. B. burgdorferi B31 contains 9 circular and 12 linear plasmids. By far, 
the plasmid-encoded content (600 kb; 670 ORFs) contains more elements 
(92% vs. 30 %) unique to B. burgdorferi than the linear chromosome (1 Mb; 
853 ORFs), but has less coding sequences (68% vs. 93%) (84). 
7.2 Expression and purification of complement components 
(I-V) 
Human complement components were (a) purified from human plasma (85, 
86), which was obtained from healthy laboratory workers, or (b) obtained from 
commercially available sources (Calbiochem, La Jolla, CA, USA). FH and FI 
were obtained both by purifying (a) and from Calbiochem (b). The latter FH 
stocks were used for the majority of the experiments, including all Biacore 
measurements. Human C5 was purchased from Calbiochem (La Jolla, CA, 
USA). Recombinant proteins FHL-1 (87) (see Fig. 1), SCRs 8-20 and SCRs 
15-20 of FH, FH-related proteins FHR-3 and FHR-4 and a construct SCR 1-4 
of FHR-3 were expressed with the baculovirus expression system as 
described earlier (88-91) by Dr. Peter Zipfel’s group and Dr. Jens Hellwage 
and/or Dr. Sakari Jokiranta, and were a generous gift to us. The recombinant 
proteins had been purified by Ni2+-chelate chromatography as described (92). 
FH and C3 were purified from human plasma (93) and C3b was generated 
from C3 with factors B and D in the presence of Ni2+ ions as described 
previously (85, 94). C4b was purchased from Quidel Corp. (La Jolla, CA, 
USA) and Dr. Anna Blom (University of Lund, Sweden) generously donated 
C4bp. C3b, C4b, FH and FHL-1 were radiolabeled with 125I using the Iodogen 
method (95) (Pierce Chemical Group, Rockford, IL, USA).  
The carboxy-terminal part of mouse FH containing SCR domains 18-20 was 
generated by PCR (see Table 1) from the clone containing full-length cDNA of 
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mouse FH DNA to amplify the region encoding SCR18-20 of murine FH. 
Human FH fragments SCR18-20 and SCR19-20 were similarly amplified 
(Cheng et al., manuscript in preparation) from a human liver cDNA library 
(Stratagene, La Jolla, CA, USA).  
Target Primers
5´-GGA TTG GAC CCT GCA GAA GCA AAG ATA A-3´Human FH
SCR18-20 3’-GGT TGA ACA CGT TTT TCT ATC GGC GCC-5’
5´-GGA TTG GAC CCT GCA GAA GCA AAG ATA A-3´Human FH
SCR19-20 3’-GGG TGA ACA CAT GTT TTA GTA CAG CTG-5’
5'-GA ATT CAA AAA GAT TCT ACA GGA AAA TGT G-3'Mouse FH
SCR18-20 3’-GGT TGA ACA CGT TTT TCT ATC GGC GCC-5’
Table 1 FH primers for generation of SCR18-20 fragments. 
The purified PCR products were expressed in Pichia pastoris strain X33, 
which was transformed by electroporation (Bio-Rad Gene Pulser II; BioRad, 
Hercules, California, USA) using expression vectors pPICZ?A and pPICZ?B
(Invitrogen, Carlsbad, California) (mouse and human FH fragments and a 
polyhistidine (His-6) tag, respectively). The transformed cells were grown on 
YPDS (Yeast Extract Peptone Dextrose Medium) plates containing Zeocin 
(100 ?g/ml; Cayla, Toulouse, France) at 30°C for 3 days, and the clones 
were selected according to the manufacturer’s protocol. The recombinant 
proteins were expressed in BMMY (Buffered Methanol-complex Medium) 
medium (1% yeast extract, 2% peptone, 100 mM potassium phosphate, pH 
6.0, 1.34% YNB (Yeast Nitrogen Base), 4 x 10-5% biotin, 1% methanol) with a 
daily addition of methanol (1% v/v) before harvesting.  
The expressed recombinant proteins were purified using Ni2+ NTA agarose 
(Invitrogen, Carlsbad, CA) according to the manufacturer´s protocol. Heparin 
affinity chromatography (Pharmacia, Uppsala, Sweden) with a Hitrap heparin 
column and elution with a 50-200 mM salt gradient was used for further 
purification. The purity of the recombinant proteins was found to be > 95% 
(moH18-20 and huH18-20 fragments were expressed as glycosylated forms) 
by sodium dodecyl phosphate polyacrylamide gel electrophoresis (SDS-
PAGE). The antigenicity of the fragments was verified by immunoblotting 
analysis using goat anti-human FH antiserum (Calbiochem, La Jolla, CA). The 
protein concentrations were determined by BCA Protein assay (Pierce 
Chemical Corp., Rockford, IL).
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7.3 Classification and culture of bacterial strains (I, II, V) 
The genospecies-classification of the Borrelia strains was determined by 
sequencing PCR-amplified fragments of the flagellin gene of B. burgdorferi
(92). PCR primers FL7 (biotinylated) and FL59 were used to obtain a 277 bp 
segment of the flagellin gene (96). The biotinylated PCR products were 
rendered single stranded using streptavidin-coated Dynabeads according to 
the instructions of the manufacturer (Dynabeads M-280 streptavidin; Dynal 
AS, Oslo, Norway). We performed manual sequencing by using Sanger's 
dideoxynucleotide chain termination method and Sequenase 2.0 (United 
States Biochemical Corp., Cleveland, Ohio, USA) as described previously 
(97). The obtained sequences were compared to the flagellin gene sequences 
Strain Origin Papers
B. burgdorferi s. s.   
IAI CSF, LD-patient (98). II
B31 USA, Patient III
297 USA, Patient III, IV
N40 USA III, IV
B. afzelii
A91 Skin, LD-patient, 1996 II
570 Tick, Helsinki 1996 II
1082 LD-patient II
B. garinii
3/96 EM-lesion, Turku 1996 II
5/96 EM-lesion, Turku 1996 II
13/96 EM-lesion, Turku 1996 II
28/97 EM-lesion, Turku 1997 II
40/97 EM-lesion, Turku 1997 II
46/97 EM-lesion, Turku 1997 II
50/97 EM-lesion, Turku 1997 II, IV
BITS University of Trieste, Italy, Gift from 
Marina Cinco
V
PIST University of Trieste, Italy, Gift from 
Marina Cinco 
V
LU59 st 5 CNS-infection, Umeå University V
LU185 st 6 CNS-infection, Umeå University V
LU190 st 6 CNS-infection, Umeå University V
LU222 st 6 CNS-infection, Umeå University V
FAR03 Puffin blood, reisolated from C3H/HeN 
mice, Umeå University 
V
FAR04 Puffin blood, reisolated from C3H/HeN 
mice, Umeå University
V
Table 2 B. burgdorferi strains used. Most strains were obtained from The 
National Public Health Institute (NPHI), Department in Turku. 
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of the type strains of B. afzelii Bo23 and B. garinii 387. B. afzelii  A91/96 and 
B. garinii 40/97 are low-passage (< 5 in vitro passages) strains and B.
burgdorferi s. s. IA is a high-passage strain. 
The strains used and their sources are shown in Table 2. Four B. garinii
strains (LU59 serotype (st) 5, LU185 st 6, LU190 st 6, LU222 st 6) isolated 
from patients with CNS-infection and two additional strains originally isolated 
from puffin blood (FAR03, FAR04) and reisolated from C3H/HeN mice were 
obtained from Pär Comstedt and Sven Bergström, Umeå University, Sweden. 
All isolates were grown in BSK-H medium containing 6% heat-inactivated 
rabbit serum (Sigma Chemicals, St. Louis, MO, USA) at 33°C in 1-5% CO2
atmosphere for two weeks or until the cultures reached late exponential 
phase. The concentration of bacteria was estimated by counting at least three 
microscope fields at 40-fold magnification. Cultures were harvested by 
centrifugation, washed and diluted to a final concentration of 2 x 107 - 1 x 109
ml in veronal buffered saline (VBS), pH 7.4 or 1/3 GVB (1/3 x VBS with 0.1% 
gelatin), and subsequently used in experiments. 
B. burgdorferi strain 297 and B. garinii strain 50 were cultivated in BSK II 
medium supplemented with 6% rabbit serum as previously described (114). 
Cloning and protein purification experiments were performed using E. coli
DH5?. Plasmid pGEX-4T-3 (Pharmacia Biotech Inc, Piscataway, N.J.) was 
used for the generation of glutathione S-transferase (GST)-fusion proteins. 
7.4 Serum sensitivity test (I, II, V)  
Borrelia bacteria were cultured until a density of at least 107/ml was reached. 
We extracted serum from a healthy laboratory worker without B. burgdorferi
antibodies. A vial of blood covered with Parafilm was let to stand still for 30 
min and centrifuged. The separated serum was then aliquoted, and frozen (-
70°C) in plastic tubes. Bacteria were centrifuged (6000 g) and washed three 
times with BSK-II buffer. For the serum sensitivity test, the reaction mixtures 
were set up to a volume of 100 µl consisting of bacteria (50 µl/reaction) and 
diluted serum. Serum was diluted with the BSK-II medium to set up five 
different reaction mixtures for each strain: 10% normal human serum (NHS), 
20% NHS, 40% NHS, and heat inactivated serum. The mixtures were 
incubated at 37°C with shaking for a total of 16 hours and 10 µl aliquots were 
pipetted onto microscope slides for analysis at 2, 5 and 16 hours using an 
Olympus microscope with dark field. The number of bacteria and the 
percentages of live (mobile) bacteria were estimated by counting several 
fields. Survival was categorized into one of the following groups: 100%, 75%, 
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25%, 5% or 0% live bacteria at each time point. The strains were classified as 
either sensitive or resistant based on the endpoint category at 16 hours. The 
serum sensitivities of a B. garinii 50 and a B. garinii 50 strain (T50) 
transfected with a plasmid containing the ospE-gene from strain 297 and 
confirmed to be expressing OspE-297 were compared as previously 
described (I, V). The ospE-297-containing plasmid was maintained using 
kanamycin-selection in culture until commencement of the experiment (V). 
7.5 FI cofactor assay (I) 
Borrelia bacteria (approximately 4 x 107) were incubated in the presence of FI 
(500 ng) and radiolabeled C3b or C4b (50,000 cpm) at 37°C for 1.5 h in 40 ?l
of VBS containing 0.1% gelatin (GVB) to prevent adhesion of the reactants to 
surfaces of the reaction tube. After incubation, the samples were 
electrophoresed in 8% SDS-PAGE gels under reducing conditions. The gel 
was fixed in 5% acetic acid for 30 min, dried and autoradiographed using the 
Fujifilm BAS 2500 instrument (Fuji Photo Film, Tokyo, Japan). 
The assay included positive and negative controls. As negative controls the 
C3b and C4b degradation assays were carried out in the absence of Borrelia
bacteria, or in the presence of selected strains of Escherichia coli,
Staphylococcus aureus and Enterococcus faecalis instead of B. burgdorferi.
The control bacteria were isolated at the Helsinki University Central Hospital 
diagnostics laboratory and selected randomly for the assay. The positive 
control mixture consisted of FH (5 ?g/ml or 0.5 ?g/ml), FI and 125I-C3b or 
C4bp (10 ?g/ml), FI and 125I-C4b. In addition, a sample of 125I-C3b or 125I-C4b 
without FI and FH/C4bp were used to monitor for any spontaneous 
degradation under the experimental conditions. 
7.6 Binding of FH and FHL-1 to whole bacteria  
The Borrelia spirochetes were cultured as described above. B. burgdorferi s. 
s., B. afzelii, B. garinii or S. aureus (used as a negative control) were used at 
a concentration of 2 x 107 cells /ml in 1/3 x VBS, pH 7.4 containing 0.1% 
gelatin (GVB). In the binding assay, the indicated amounts of bacteria were 
incubated for 20 min at 37°C with the 125I-labeled FH or FHL-1 (60,000 cpm) 
in a total volume of 100 ?l of 1/3 x GVB (90). Particle-associated FH/FHL-1 
was separated from unbound ligand by centrifuging the mixtures through 20% 
sucrose in 1/3 x GVB. The tube was then frozen at –80°C to avoid mixing the 
supernatant with the pellet. After cutting off the pellets, the binding of the 
FH/FHL-1 proteins was calculated as a percentage of the total radioactivity 
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input. All experiments were performed a least in duplicate. For the heparin 
inhibition assay, varying amounts of heparin (Sigma Chemicals, St. Louis, 
MO, USA) were added to the reaction mixture simultaneously with FH/FHL-1. 
7.7 SDS-PAGE and Western blot analysis (I, V) 
In SDS-PAGE analysis proteins were separated through 4% stacking and 
10% separating gels. The proteins were transferred to nitrocellulose 
membranes for Western blot analysis. The membranes were blocked with 5% 
(w/v) dried milk in phosphate buffered saline (PBS) for 30 min and incubated 
at room temperature for 1 h with polyclonal goat anti-human FH antibody 
(Calbiochem, La Jolla, CA; diluted 1:5000). This antibody also recognizes 
human FH-like protein 1 (FHL-1) and the family of FH-related proteins (FHR-1 
to FHR-5). A donkey anti-goat IgG antibody (Jackson ImmunoResearch 
Laboratories, West Grove, Pennsylvania; diluted 1:5000) was used as the 
secondary antibody.  
5 ? 107 organisms of B. burgdorferi strain 297, B. garinii strain 50 and 200 ng 
of recombinant OspE protein were boiled for 10 min in final sample buffer 
(62.5 µM Tris-HCl [pH 6.8], 10% [vol/vol] glycerol, 5% [vol/vol] ?-
mercaptoethanol, 5% SDS, 0.001% bromophenol blue) and subjected to 
SDS-PAGE through a 12.5% separating gel before being electroblotted onto 
nitrocellulose membrane (Schleicher and Schuell, Keene, N.H.).  To 
determine the reactivity of B. burgdorferi strain 297 and B. garinii with OspE 
antibody, the membrane was first blocked in blocking buffer (5% non fat dry 
milk in PBS, 0.2% Tween-20) overnight at 4°C before being washed and 
incubated with a 1:1000 dilution of rat anti-OspE serum for 1 hr.  This was 
followed by three washes with blocking buffer before a 1:5000 dilution of 
HRP-conjugated goat anti-rat antibody (Zymed, San Francisco, CA) was 
added for 45 min.  The nitrocellulose was then washed three times prior to 
detection by enhanced chemiluminescence according to the manufacturer’s 
recommendations (Amersham Pharmacia).  To ensure equivalent loading of 
whole cell lysates, the same membrane was subsequently blotted with rabbit 
anti-FlaB antibodies as described above using goat anti-rabbit HRP as the 
conjugate. 
7.8 Immunoblotting and ligand blotting analysis of FH 
binding (I, V) 
FH binding by Borrelia strains directly from the growth medium or from human 
plasma was also analyzed by an immunoblotting assay. B. burgdorferi strains
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that had been grown in the BSK-H medium or incubated in human EDTA 
plasma and washed for 3 times with VBS were mixed with a reducing SDS-
PAGE sample buffer. The samples containing 107/ml bacteria were incubated 
at 37°C for 20 min on a shaker, and aliquots were run in an 8% SDS-PAGE 
gel. The samples were electrotransferred onto a nitrocellulose membrane and 
the membrane was blocked with 5% fat free milk in PBS. Polyclonal goat 
anti-FH antibody (1:5000 dilution) was added and the membrane incubated 
for 12 hours at +4°C. The membrane was washed 5 times, a secondary 
peroxidase-conjugated donkey-anti-goat antibody (1:5000 in 1% BSA/PBS) 
was added and incubated with the membrane for 60 min at RT on a shaker. 
The membrane was washed with PBS and positive reactions were visualized 
by the electrochemiluminescence (ECL) method (Amersham, Amersham, 
UK). To analyze binding of radiolabeled FH or FHL-1 to borrelial proteins 
separated in an SDS-PAGE gel a radioligand blotting analysis was employed. 
For the radioligand blotting analysis of FH and FHL-1 binding, outer 
membranes (OM) and protoplasmic cylinders (PC) of one strain of each 
genospecies of Borrelia bacteria were isolated using a method described 
previously (I). The OM and PC specimens were run in an 8% SDS-PAGE gel 
under non-reducing conditions and transferred onto a nitrocellulose 
membrane. The membranes were blocked with 5% fat free milk in PBS for 60 
min at RT. 125I-labeled FH and FHL-1 (1x106 cpm/membrane) were incubated 
on the membranes for 24 hours at +4°C on a shaker. The membranes were 
washed five times with PBS and analyzed by autoradiography.   
7.9 Immunofluorescence microscopy analysis of 
complement deposition (II, III) 
B. burgdorferi s. s. (strain IA), B. afzelii (strain 1082) and B. garinii (strain 50) 
were cultured as described above. Freshly harvested (s. s. IA, 6.4 x 107) or 
frozen bacteria (garinii 5.4 x 109 and afzelii 6.4 x 109) were washed with GVB 
and incubated 1:2 with non-immune NHS (no IgG or IgM -antibodies against 
B. burgdorferi were detected by ELISA (99) or EDTA-plasma from the same 
donor for 60 min at +37°C. Bacteria were washed three times with GVB and 
incubated with a monoclonal antibody against iC3b (Quidel Corp., La Jolla, 
CA, USA). For detection of FH and FHL-1, we used the 196x mAb 
recognizing the N-terminus (SCR 1) of FH and mAb VIG8 (kindly provided by 
Dr. Wofgang Prodinger, University of Innsbruck) (89) for specific detection of 
the C-terminus (SCRs 19-20) of FH. An unrelated B-cell lymphoma idiotype-
specific AF1-antibody served as a control. Samples were incubated for 30 min 
at +37°C with primary antibodies (10 ?g/ml) and washed three times with 
GVB before adding a polyclonal FITC-conjugated goat anti-mouse IgG 
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(Alexa 488, Molecular Probes, Oregon, USA) used in 1:200 dilution. The 
stained samples were mounted with Mowiol (100) and examined on an 
Olympus BX50 standard microscope equipped with a filter specific for FITC 
fluorescence. The samples were photographed with a Spot RT Slider digital 
camera and processed with Spot RT Software 3.0 (Diagnostic Instruments, 
Sterling Heights, MI, USA). 
7.10 Analysis of borrelial surface protein expression by 
immunofluorescence microscopy 
To analyze expression of surface proteins of B. burgdorferi within ticks, mid-
guts were dissected out of B. burgdorferi strain 297 infected ticks (nymphal 
stage) prior to feeding (n = 12) or after feeding to repletion (n = 10). Extracted 
mid-guts were diluted in 20 µl PBS (pH 7.4) before being disrupted by 
repeated pipetting.  Ten µl of each sample (mid-guts from unfed or fed ticks) 
were spotted onto fluoro-slides (Erie Scientific) and indirect 
immunofluorescence assays were performed as described previously (101).  
For these experiments, rat polyclonal antiserum directed against OspA, 
OspC, OspE, ElpB1, or OspF was used as the primary antibody at 1:25 
dilutions.  Alexa 488 labeled goat anti-rat IgG (heavy and light chain specific) 
was diluted in PBS-0.2% BSA at 1:1000 and used as the secondary 
antibodies.  Slides were washed and fixed in acetone before fluorescent 
imaging was performed.  For each protein analyzed, multiple fields were 
viewed before images of representative fields were captured using a Spot 
digital camera and associated software (Diagnostic Instruments, Sterling 
Heights, Michigan). 
7.11  Expression and purification of recombinant borrelial 
surface proteins 
B. burgdorferi s. s. strain N40 OspE protein (Table 3; (102)) DNA 
corresponding to the mature portion of the OspE gene was cloned into a 
pGEX-2T vector (Pharmacia, New Jersey, USA) in Michael Norgard’s lab, 
Dallas, USA. We expressed the GST-OspE fusion protein in E. coli DH5-
alpha host cells. Fresh transformants selected from a single colony were 
cultured in 50 ml of Luria-Bertani (LB) broth containing 100 mg/ml ampicillin at 
37°C with shaking overnight. The culture was diluted 1:100 to 1500 ml of LB 
broth containing 100 mg/ml ampicillin, incubated at 37°C for 3 hours to reach 
the mid-log phase with an optical density of approximately 0.6 at 600 nm. The 
culture was incubated for an additional three hours in the presence of 
Isopropyl-?-D-thiogalactoside (IPTG) 0.6 mM. The GST-OspE fusion protein 
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was then purified from harvested, washed and sonicated cells by affinity 
chromatography on an agarose-glutathione matrix according to the 
instructions of the manufacturer (Amersham Pharmacia Biotech, Sweden). 
Bovine thrombin was used to cleave OspE from GST (Sigma, USA) in 
thrombin cleavage buffer (150 mM NaCl, 100 mM KCl, 2.5 mM CaCl2, 1 mM 
DTT, 20 mM Hepes pH 7.6) for 3 h. and. The cleaved OspE was then eluted 
with TCB and dialyzed in an 11 mm Spectrapore membrane tube (Spectrum 
Medical Industries, Rancho Dominguez, CA, USA) against 10 mM 
diaminopropane pH 8.6 for 20 h. The dialysed OspE was applied on a MonoQ 
(Pharmacia, Uppsala, Sweden) column and eluted using NaCl. The purity of 
the OspE protein was thereafter confirmed by SDS-PAGE. 
B. burgdorferi s. s. 297 OspA, and B. burgdorferi s. s. N40 OspD (Table 3) 
were cloned originally in Michael Norgard’s lab, Dallas Texas. Outer surface 
lipoproteins (Table 3) from Borrelia burgdorferi s. s. 297 and B31 strains were 
expressed in E. coli as GST or polyhistidine-tagged fusion proteins and 
purified as previously described (101, 103, 104). Polyhistidine-tagged ErpA, 
ErpP, ErpL and ErpX proteins (Table 3) were generated by cloning PCR-
amplified products (Table 4) representing the mature portion of each protein 
using the respective primers. The GST moiety was removed from all fusion 
proteins with thrombin prior to use in the binding assays. All resulting 
constructs were sequenced to confirm that the inserted DNA was in frame 
and that no errors were incorporated during PCR amplification. Fusion 
constructs were grown in tryptone-yeast broth supplemented with 100 ?g of 
ampicillin to an OD600 of 0.7 before arabinose was added to a final 
concentration of 0.2% to induce expression of the fusion proteins. Remaining 
proteins were hyperexpressed like OspE. Polyhistidine-tagged proteins were 
affinity-purified using nickel chromatography as instructed by the 
manufacturers (Amersham Pharmacia, Piscataway, NJ, USA and Invitrogen, 
Carlsbad, CA, USA). The hexa-His fusion proteins were purified by affinity 
chromatography using a chelating Sepharose Fast Flow matrix containing 
Ni2+-ions and eluted from the column by increasing the amount of imidazole. 
SDS-PAGE was used to confirm the purity of the proteins. Other proteins 
were purified similarly to OspE.  
7.12 Generation and purification of P21 deletion mutants and 
synthesis of C-terminal peptides (IV, V) 
P21 is an OspE-paralog from the B. burgdorferi s. s. 297 strain. The truncated 
versions of P21 lacking the N-terminus (P21?1-35) or C-terminal regions of 
varying lengths (P21?105-166, P21?143-166 and P21?152-166) were made 
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Target Primers 
5'-GCG GAT CCA AAT TTA CTG TAA AAA TTA AAA-3’ P21?1-35 
3’-CTA GAA TTT TTT TTA AAT TTT CAG CTG CCG-5’ 
P21?1-45 5'-GCGGGATCCGAGTTAAAACTTAAAAAAATAGAATT-3' 
3’-TTCTAGAATTTTTTTTAAATTTTATCATCGAGCTCGCG-5’
5’-GCG GAT CCT GCA AAA TTC ATA CTT CAT ATG-3’ P21?105-166 
3’-CCA AGC AAA TTT TGA CTA CTC CAG CTG CCG-5’ 
5’-GCG GAT CCT GCA AAA TTC ATA CTT CAT ATG-3’ P21?143-166 
3’-ATA TAA TGT AAA AGT CCT TTA CAG CTG CCG-5’ 
5’-GCG GAT CCT GCA AAA TTC ATA CTT CAT ATG-3’ P21?152-166 
3’-C CTA AGG CCC CTA TTT CAA CAG CTG CCG-5’ 
7.13 Surface plasmon resonance assays (III, IV, V) 
Protein-protein interactions were analyzed in real time using surface plasmon 
resonance (SPR) with a Biacore 2000? instrument as previously described 
(90, 91). FH or recombinant surface proteins (P35/BBK32, OspC, OspE) were 
coupled via a standard amine-coupling procedure to flowcells of a sensor chip 
(carboxylated dextran chip CM5; Biacore AB, Uppsala, Sweden). Flowcells 
were activated with 35 ?l of a mixture of 0.2 M N-ethyl-N’-(dimethyl-
aminopropyl)-carbodiimide and 0.05 M N-hydroxysuccinimide (NHS-EDC; 
Biacore AB). The protein to be immobilized was dialyzed against 10 mM 
acetate buffer (pH 4.8 – 5.5) and 20 ?g (> 150 ?g/ml) were injected into one 
of the flowcells until an appropriate level of coupling for the binding 
experiments (> 4.000 resonance units (RU)) was reached. A control flowcell 
with no protein was similarly activated. Unreacted groups in both flowcells 
were inactivated by a standard ethanolamine-HCl (Biacore AB) injection (35 
?l). After the coupling procedure, the flowcells were washed thoroughly with a 
sequential injection of 1/3 x VBS (50 mM VBS pH 7.4) and 3 M NaCl in 10 
mM acetate buffer, pH 4.6. 
Target Primers
5'-TGCAAAGCAATGGAGAGGTAAAGGTC-3’erpA
3’-CTTCTCGAATTTTCTTTAAATTTT-5’
5' TGCAAAATTCATACTTCATATGATGAG-3’erpP
3’-GGTGATCTTCACGAATTTTTTTTAAATTTT-5’
5'-TGCAAGAATTATGCAAGTGGTG-3’erpL
3’-CCCTTATCTTCTTCTATTTTTTCTT-5’
5' TGCAAGATTGATGCAACTGGTAAAGATGC-3’erpX
3’-CTTTAATTTCCTATGTAGTCAATGTCAGTC-5’
Table 4 Primers used in expression of Erp-proteins in recombinant form. 
Table 5 Primers used for construction of P21-mutants. Sites added for cloning 
are underlined. 
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First, the binding of a panel of Borrelia surface proteins (OspA, OspC, OspD, 
OspE, P35/BBK32, DbpA) to FH was tested. The proteins were dialyzed 
against 1/3 VBS and protein concentrations were measured using the BCA 
Protein Assay (Pierce Chemical Company, Rockford, IL). Each ligand was 
injected separately to a blank control flowcell and the flowcell with the analyte 
using a flow rate of 5 ?l/min at +22°C. The final concentrations of the fluid-
phase ligands in the binding assay ranged from 125 to 200 ?g/ml. In a 
second set of experiments, a reverse setting was used. The Borrelia surface 
proteins were immobilized to the sensor chip surface as described above. The 
binding of FH, recombinant deletion constructs of FH or FH-related proteins 
was tested using by injection of the proteins to a flowcell with Borrelia surface 
protein and to a blank channel. Binding was assayed at least in duplicate 
using independently prepared sensor chips.  
Strain Protein Sequence
B. burgdorferi s. s. 297 OspE Biotin-GABA-KVAEYAISLEELKKNLK
B. burgdorferi s. s. 297 P21 Biotin-GABA-KIKNSKNKVAEYAILLENLKKNLK
B. burgdorferi s. s. B31 ErpP Biotin-GABA-KINNGVGGNKTAEYAIPLEVLKKNLK
N/A S-ErpP Biotin-GABA-KINNGVGGNKTAEYAIPLEVLKKKFK
OspE 5’-TGTGGAAATTTTAGAAGTAGTTTAAGTG-3’ 
B. garinii BITS & B. garinii 40/97 
OspE 3’-CTTGTATAATGTAAAAGTCCTCTATTTAA-5’ 
For coupling of OspA, OspE, P21, OspF, Bbk2.10, Bbk2.11, OspE, OspD, 
ElpA1, ElpA2, ElpB1, ElpB2, ErpA, ErpP, ErpL, ErpX, OspE-40/97, and 
OspE-BITS the buffer was chosen according to the pI of the analyte: maleate 
and sodium acetate buffers were used for proteins whose calculated pI values 
were over or below 6, respectively. If poor results were obtained, the buffer 
pH was lowered. The coupling levels of proteins varied between 500-3000 
resonance units (RU). The binding of complement FH (Calbiochem, San 
Diego, California; purity > 95% by SDS-PAGE) to immobilized proteins was 
assayed at 22°C and 37°C or only at 25°C. Recombinant OspE- OspF- and 
Elp-family proteins were coupled to a CM5-chip and the binding of fluid phase 
FH was analyzed. FH at different concentrations in 50 mM VBS was used as 
the ligand. A set of adjusted pH-values and a series of different FH 
concentrations in 150 mM PBS were used to examine the pH-dependence of 
binding. The binding kinetics was fitted to the simultaneous ka/kd 
determination feature of the BiaEvaluation 3.1 software package and a natural 
logarithmic Langmuir binding (1:1) and mass transfer model. For OspE-40/97 
and P21-297 comparison strain the calculations were made using the 
SigmaPlot 8.0 software package.  The sequences of the proteins used in the 
Table 6 B. burgdorferi C-terminal peptides from OspE-related proteins and
primers used for amplification of B. garinii OspE for sequencing. N/A, not
applicable, S-ErpP, scrambled ErpP sequence. 
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Biacore assays and peptide mapping were retrieved from the NCBI sequence 
database and aligned using the ClustalX 1.8 software package (106) 
(http://www-igmbc.u-strasbrg.fr/BioInfo/clustalx, ftp://ftp-igmbc.u-strasbrg.fr). A 
phylogenetic analysis was performed based on sequence comparisons of the 
proteins; ClustalX was used to generate an N-J-tree, which was plotted using 
the Phylip software package (107). 
For P21-mutants, the following method was used. Purified mutant P21-297 
proteins (5.6 ?M) were amine-coupled to carboxyl groups of CM5 sensor 
chips according to the manufacturer’s instructions. The buffer was chosen 
according to the pI of the analyte: maleate and sodium acetate buffers were 
used as above. The binding of complement FH (Calbiochem, San Diego, 
California; purity > 95% by SDS-PAGE) to immobilized proteins was assayed 
at 25°C in 50 mM VBS. Similar binding tests were performed with the biotin-
GABA-linked C-terminal peptides of OspE proteins. The peptides were 
coupled to an SA-chip and tested for FH binding ability (see Table 7). The 
binding of recombinant human FH fragments huH18-20 (0.044 mM) and 
huH19-20 (0.10 mM) and the recombinant mouse FH fragment moH18-20 
(0.061 mM) to P21-297 was analyzed similarly using VBS as a buffer. The 
bound proteins were removed with a regeneration buffer containing 3.0 M 
NaCl (pH 4.7). To see if binding of FH could be inhibited by heparin, FH (300 
nM) binding to P21 was assayed in the presence of 0.3 or 3.0 ?M heparin 
17/19 kDa (Sigma Chemicals, St. Louis, MO). Similar inhibition analyses were 
performed with the deletion mutants of P21 and soluble C-terminal P21 
peptides (see below). P21?1-45 and Bba68 were coupled in sodium acetate, 
pH 4.0-5.0 to a CM5-chip to achieve coupling levels of several thousand RU.  
The proteins were amine-coupled and the binding of complement FH was 
assayed as above. B. garinii OspE proteins from the BITS and 40/97 strains 
were tested for FH binding activity and compared to P21-297. Also, FH 
subunits containing only SCRs 18-20 or 19-20 were used as ligands in the 
Biacore assays. Biacore testing was done similarly to OspE-proteins (see 
above). FH was applied to the chip in PBS, pH 7.48.
Protein P21 amino acids  CM5 coupling level (RU) Paper
P21  
P21  
1-166 2468; (Figs. 2, 4A) 
3403; (Figs. 4B, 5) 
IV
IV
P21?1-35 36-166 1990 IV
P21?1-45 46-166 970 V
P21?105-166 1-104 7439 IV
P21?143-166 1-142 2293 IV
P21?152-166 1-151 9284 IV
Table 7 P21-mutants and their coupling levels in Biacore?.
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7.14 Peptide mapping and alanine scanning (III, IV) 
The candidate protein sequences chosen for peptide mapping analysis from 
the NCBI protein sequence databank (http://www.ncbi.nlm.nih.gov) (108) are 
shown in Table 8. P21-DK1 is an OspF family member from B. afzelii DK1.  
OspE-IP90 is a C-terminally truncated sequence from the B. garinii IP90 
strain that does not bind FH. All sequences were fragmented into 15 amino 
acid (aa) peptides with a 3 aa transition and a 12 aa overlap. The peptides 
were synthesized as spots onto polyethylene glycol -derivatized cellulose 
membranes (AIMS Scientific Products, Braunschweig, Germany; 
http://www.aims-scientific-products.de) using the peptide scanning instrument 
Auto-Spot Robot ASP222 (Abimed Analysen-Technik Gmbh, Langenfeld, 
Germany). Subsequently, a protein overlay assay with radiolabeled FH (II, 
(91)), I) was carried out. The membranes were washed and exposed on a 
phosphoimager plate. Amino acid sequences of the tested proteins were 
aligned using the Megalign and ClustalX programs.  
Strain Protein NCBI Reference 
OspE (cp32-2) AAC34953 (103) B. burgdorferi s. s. 297 
P21 (cp18-2) AAC34957 (103) 
ErpA (cp32-1) AAF07400 (109) B. burgdorferi s. s. B31 
ErpP (cp32-9) AAF07678 (109) 
B. burgdorferi s. s. N40 OspE AAA22959 (110) 
B. afzelii DK1 P21 CAA69689 
B. garinii IP90 OspE AAC62927 
Table 8 OspE-related and control proteins screened for FH binding using 
Biacore and peptide scanning (III). 
The Megalign and ClustalX-programs were used to align the amino acid 
sequences of the tested proteins (Table 8). Sequences from five putative FH-
binding regions (III) were chosen from ErpA and from the proteins giving the 
strongest FH-binding signal strength for each region. We incorporated single 
alanine mutations into all aa-positions in the sequences in separate peptides. 
The membranes were washed and exposed on an X-ray film (Fuji Photo Film 
Co Ltd, Tokyo, Japan), which was thereafter scanned and processed using 
Adobe Photoshop 6.0.  
7.15  The GST-fusion protein pull-down technique (IV) 
To identify potential Borrelia OspE -interacting proteins in human serum, a 
GST-fusion construct of B. burgdorferi s. s. strain N40 OspE (Table 3) was 
generated as previously described (I) and used as an analyte in a GST-OspE 
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pulldown technique (111). Both NHS and serum from a volunteer deficient in 
the FH-related protein 1 (FHR-1DS) were used. Serum samples were 
incubated with glutathione-sepharose 4B (Amersham Biosciences, Freiburg, 
Germany) beads (1 ml serum + 50 ?l of 50% slurry) for 2 h at 4 ºC with gentle 
mixing and then centrifuged (20,800 g, 2 min) to collect the supernatants. Pre-
cleared sera were used at dilutions 1:2 and 1:10. GST (10 ?g) was added to 
the control tube of and GST-OspE (~16 ?g) was added to the other tubes, 
followed by gentle mixing for 2 h at 4 ºC. The beads were washed three times 
with PBS and bound proteins were eluted by adding 50 ?l of 20 mM reduced 
glutathione. After centrifugation, the supernatants containing the eluted 
proteins were collected for further analysis. 
7.16 Sequencing and sequence comparisons (V) 
Amplicons from B. garinii BITS and B. afzelii 40/97 were generated using 
PCR-primers (Table 6). The resulting amplicons were cloned into the pCR-
TOPO vector (Table 3) (Invitrogen Life Technologies, Carlsbad, CA) and 
individual clones for each strain were subjected to nucleotide sequence 
analysis. Sequencing was performed with the universal T7 and M13 reverse 
sequencing primers at the OUHSC, core DNA sequencing facility using an 
Applied Biosystems Inc. model 373A automated DNA sequencer and PRISM 
ready reaction DyeDeoxy terminator cycle sequencing kit according to the 
manufacturer’s instructions (Applied Biosystems Inc., Foster City, CA).  All 
nucleotide and deduced amino acid sequence analyses were performed using 
the MacVector version 6.5.3 software package (Oxford Molecular Group, 
Campbell, CA).  Multiple sequence alignments and phylogram analyses were 
performed using the ClustalW multiple sequence alignment program of the 
MacVector version 6.5.3 software package. 
Sequence comparisons were carried out between OspE-related proteins from 
serum sensitive B. garinii IP90 and serum resistant B. burgdorferi s. s. 297 
and B. afzelii strains using the GoCore sequence analysis tool (112), which 
highlighted sequence differences most likely associated with observed 
differences in serum resistance. Also, most likely antibody binding sites were 
screened using GoCore. 
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8 Results 
8.1 Serum sensitivities of Borrelia species (I, V) 
The serum sensitivities of various strains of B. burgdorferi were tested by 
incubating the bacteria in 10%, 20%, and 40% NHS for 16 hours at +37°C. 
Samples from the reaction mixtures were taken at 2, 5 and 16 hours for 
microscopy, and the survival percentages of bacteria were estimated. B. 
burgdorferi s. s. IA, B. afzelii 1082 and B. afzelii A91 were classified as 
resistant and B. garinii 3/96, 5/96, and 46/97 as sensitive at the 16 hour 
timepoint. We also analyzed a tick isolate of B. afzelii 570, but we included 
only the patient isolates in the final analysis. The tick strain was resistant at 
the first two timepoints, but its survival declined at the 16-hour timepoint, 
possibly due to a lower adaptation to survival in serum. 
Because of the observed differences in serum sensitivity, we next compared 
the ability of the various Borrelia genospecies to promote C3b cleavage. 
When 125I-C3b was incubated with B. afzelii (A91) and FI for 1.5 h at 37°C, a 
distinct C3b degradation pattern was observed. The ?’–chain of C3b became 
cleaved into 68 kDa, 46 kDa and 43 kDa fragments. The amount of cleavage 
products showed a dose response with an increasing concentration of 
bacteria and the pattern of cleavage resembled that obtained with FH and FI. 
In the absence of FI or bacteria, no cleavage of C3b took place. As controls, 
we tested other bacteria. Enterococcus faecalis, S. aureus or E. coli did not 
exhibit C3b degrading activity in the presence or absence of FI.  
When a larger panel of Borrelia strains was tested, it was observed that B. 
burgdorferi s. s. (IA) and B. afzelii strains (A91, 570, 1082) promoted cleavage 
of C3b in the cofactor assay, whereas the seven strains of B. garinii (3, 5, 13, 
28, 40, 46, 50) did not. A similar cleavage pattern was observed with all B. 
afzelii strains. The cleavage pattern obtained with B. burgdorferi s. s. was 
somewhat different from that obtained with the B. afzelii strains. Incubation of 
the B. burgdorferi s. s. IA strain with 125I-C3b and FI produced a fourth ?-chain 
41 kDa band in addition to the 68, 46 and 43 kDa bands. This cleavage 
pattern possibly indicated a more efficient C3b inactivation by B. burgdorferi s. 
s. than by B. afzelii. No cleavage occurred with either B. burgdorferi s. s. or B.
afzelii in the absence of FI, indicating that the cleavage was not due to a 
protease on the borrelial surface.  
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8.2 Complement deposition on serum-incubated Borreliae
analyzed by microscopy (I) 
In order to examine complement deposition and regulation on the borrelial 
surface, we stained spirochetes of the three subspecies with specific 
antibodies after incubation in normal human non-immune serum. Deposition 
of iC3b was detected on all three strains. An antibody specific for the C-
terminal domains SCR 19-20 of FH showed strong signals for the B. 
burgdorferi s. s. and even stronger for the B. afzelii strain, but weaker staining 
for the B. garinii strain. However, incubation of the Borrelia bacteria in NHS 
may lead to complement activation on the borrelial surface. The FH from the 
serum may then bind rather to C3b deposited on the Borrelia surface than to 
a specific ligand on the spirochete. Thus when NHS-EDTA was added, in 
which the alternative pathway activation is inhibited, signals were only 
obtained for the serum resistant s. s. and afzelii strain. The deposition on B.
garinii was much weaker. The staining was repeated with an antibody specific 
for the N-terminus of FH. In contrast to the other antibody, this antibody 
detects FH and the smaller FHL-1 protein, which represents SCR 1-7 of FH. 
The N-terminal antibody showed a weaker staining, although the signals for 
the B. garinii strain were stronger than with the other antibody. A non-
complement antibody, serving as a negative control, showed no signals at all. 
8.3  Acquisition of FH and FHL-1 from growth medium by 
Borreliae (I) 
In order to determine the mechanism responsible for the observed cofactor 
activity, we tested the possibility that the bacteria had acquired FH from their 
growth medium. The presence of FH was analyzed by immunoblotting using a 
goat antibody that recognizes both human and rabbit FH. Two different 
preparations of B. afzelii A91, two B. garinii strains (3/96, 46/97) and B.
burgdorferi s. s. IA that had been grown in the BSK-H medium were washed 
and incubated in SDS-PAGE sample buffer and run on an SDS-PAGE gel. 
Immunoblotting with the polyclonal anti-FH antibody revealed FH on the 
surfaces of B. afzelii A91 and B. burgdorferi s. s. IA strains. In addition, B. 
burgdorferi s. s. IA appeared to have bound a lower molecular weight protein 
that corresponded to FHL-1, an alternatively spliced 43-kDa product of the FH 
gene. No bound FH or the putative FHL-1 on either of the B. garinii strains 
was observed. 
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8.4 Binding of FH and FHL-1 to different strains of B. 
burgdorferi (I)
To directly analyze FH binding to B. burgdorferi, radiolabeled proteins FH and 
FHL-1 were incubated with six different strains of the three pathogenetically 
relevant B. garinii, B. afzelii, and B. burgdorferi s. s. strains. The bound 
proteins were separated by centrifugation through a 20 % sucrose solution 
and the binding quantified with a gamma counter. Sedimentation of 
radioactivity in the absence of bacteria was taken as background (always 
below 0.3 % of total offered radioactivity). Both FH and FHL-1 bound to the B. 
burgdorferi s. s. IA strain (I). The values were ten times higher for FH and five 
times higher for FHL-1 when compared to the B. garinii and B. afzelii strains. 
S. aureus and S. epidermidis were used as controls. Neither FH nor FHL-1 
bound to these bacteria.  
8.5 Binding of human FH and FHL-1 to borrelial surface 
proteins (II, III) 
B. burgdorferi s. l. has a two-layer outer membrane with very few proteins on 
the outermost membrane. In order to localize the FH binding molecule(s), 
outer membranes of strains of all three genospecies were isolated by 
ultracentrifugation through sucrose density gradients. OMs and protoplasmic 
cylinders (PC) were collected, run in SDS-PAGE and transferred onto 
nitrocellulose membranes. FH and FHL-1 binding was analyzed by incubating 
the membranes with radiolabeled FH and FHL-1. FH binding was observed to 
B. burgdorferi s. s. IA OM and PC fractions suggesting that a FH binding 
molecule is present on the outer membrane. The FH-binding proteins had 
approximate molecular weights of 19 and 35 kDa (I). FHL-1 binding was 
observed to the 35 kDa protein on B. afzelii A91 OM and PC fractions as well 
as on the B. burgdorferi s. s PC fraction. This suggests that a molecule 
binding FHL-1 can be found on the outer membrane of at least B. afzelii
strains. No binding of either FH or FHL-1 to B. garinii proteins was observed. 
The results suggested that FH and FHL-1 selectively bound to the outer 
membranes of both B. burgdorferi s. s. and B. afzelii strains. This accounted 
for the observed differences in serum sensitivity and C3b degradation 
promoting activity.   
Given the interaction between FH and the whole Borrelia bacteria, we wanted 
to identify potential ligands on the Borrelia surface. To this end we screened a 
set of six recombinantly expressed surface proteins of Borrelia: the outer 
surface proteins OspA, OspC, OspD and OspE, the Decorin-binding protein 
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DbpA and the protein P35 (also known as BBK32). This set represents a 
number of prominent proteins on the borrelial surface. For most of these 
proteins immune responses in the human host have been reported.  
As a screening method for the putative protein-protein interaction we used the 
Biacore biosensor method. FH was immobilized to the surface of the sensor 
chip by standard amine coupling. The various Borrelia surface proteins were 
injected to the flow cell containing FH and to a blank flow cell used as an 
internal control. One of the outer surface proteins, OspE, bound to FH while 
OspA, OspC and OspD did not bind. The P35/BBK32 protein showed some 
binding to FH but interacted also with the dextran-matrix of the control blank 
channel.  
To confirm the result and to simulate a more physiologic situation (borrelial 
protein on the surface and FH in the fluid phase), the analysis was repeated 
in a reverse setting. The Borrelia surface proteins OspC, OspE and P35 were 
immobilized onto the chip surface and FH was used as an analyte in the fluid 
phase. In this approach the binding of OspE to FH was confirmed, while no 
binding could be observed between FH and OspC or the P35 protein. Thus, 
FH interacts with OspE regardless of which of the binding partners is 
immobilized. OspE was hereby identified as the first specific receptor in the 
interaction with the complement regulator FH (II). 
A similar analysis was performed with complement components, C3b and C5. 
The P35 protein bound to both C3b and C5, when the latter proteins were 
coupled to the chip (data not shown). Thus, the interaction between 
P35/BBK32 and FH/C3b/C5 seems to be more due to a general 'stickiness' of 
the protein rather than to a specific interaction. Next we analyzed a set of 
OspE-related borrelial surface proteins for FH binding using SPR. We found 
OspE-related proteins to constitute a family of FH-binding proteins (III). The 
observed binding affinities are shown in Table 9. 
B. burgdorferi OspE-
protein 
Coupling level/RU Buffer t/°C Affinity 
OspE 140 1/3 VBS 25 8.23 ± 0.27 nM 
P21 359 1/3 VBS 25 8.36 ± 0.25 nM 
ErpA 1930 PBS 22 102 ± 7 nM 
ErpP 2843 PBS 22 129 ± 13 nM 
OspE 40/97 1538 PBS 25 268 nM r20,922 
P21 1522 PBS 25 20 nM r20,990 
Table 9 Measured affinities of B. burgdorferi FH-binding proteins for FH. The 
calculations have been made with either BiaEvaluation 3.0 of SigmaPlot 8.0. 
R2-values are a measure of the accuracy of the result when using SigmaPlot.  
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8.6 Mapping of the OspE binding site on FH (IV) 
To localize the binding site on FH responsible for the interaction with OspE, 
we tested a set of recombinant constructs of FH and FH-related proteins. 
OspE was immobilized on the Biacore chip surface and six different 
recombinant constructs were tested. The recombinant proteins were 
expressed in the baculovirus system and their functional activity had been 
shown earlier (e.g. binding to the complement component C3b). We tested 
the following constructs of FH: SCR 1-7 (FHL-1), SCR 8-20 and SCR 15-20. 
Surprisingly, the construct SCR 1-7 did not bind to OspE. This construct 
contains the domain responsible for the basic complement regulatory 
functions of FH in SCRs 1-4 and a domain, which has been shown to interact 
with heparin, streptococcal M protein and the C-reactive protein. A construct 
consisting of the SCRs 8-20 clearly bound to OspE. A construct SCR 15-20 of 
FH also bound to OspE, suggesting that the interacting site is located in the 
C-terminal region of the protein.  
8.7 Binding of the most C-terminal SCR-domains of human 
and mouse FH to OspE (IV) 
FH from multiple animal species binds to the borrelial outer surface protein 
OspE (II, IV, 115, 116). Thus, we wanted to localize the borrelial OspE 
binding sites on both human and mouse FH. As a representative of the OspE-
family of proteins we used the OspE-paralog P21 that is encoded by the B.
burgdorferi s. s. strain 297. Since our earlier studies suggested a binding site 
in the SCR15-20 region (II), we first tested binding of human FH constructs 
containing SCRs 18-20 or 19-20 to surface-coupled P21 using the surface 
plasmon resonance technique. A human FH construct containing SCRs 18-20 
bound to the P21-protein with a high affinity. For the shorter construct huH19-
20, both P21 association and dissociation occurred more slowly, indicating 
that the FH19-20 fragment remained strongly bound to P21. Further 
experiments showed that the mouse C-terminal FH construct moH18-20 also 
binds to P21-297.  
8.8 Binding of FHR-1 to OspE (IV) 
Since human blood plasma contains several FH-related proteins (FHR-1, -2, -
3, -4 and -5) whose C-terminal SCRs resemble those of FH, we analyzed 
whether OspE could bind to serum proteins other than FH. To identify 
potential OspE interacting proteins, NHS (1:2 or 1:10 dilution) and serum from 
an individual deficient in FHR-1 (FHR-1DS) was first precleared from any 
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GST-binding proteins and thereafter incubated with the GST-OspE fusion 
protein and glutathione-sepharose beads. The beads were separated by 
SDS-PAGE and analyzed by silver staining and Western blotting. FHR-1 was 
found to bind to OspE in a specific manner. The binding of FHR-1 to OspE is 
probably due to the three most C-terminal domains (SCRs 3, 4, and 5) of 
FHR-1, which are very homologous (100%, 100%, and 97% respectively) to 
FH SCR domains 18, 19 and 20.  
8.9  FH binding by truncated P21-297 proteins (IV, V) 
The FH sites responsible for OspE binding were analyzed among the five 
putative sites previously characterized by peptide mapping (III). We therefore 
constructed N- or C-terminal deletions of varying lengths of P21 and tested 
FH binding of the mutant-proteins in Biacore analysis. The P21-297 mutants 
were coupled to the sensor chip and human FH was used as the fluid phase 
ligand. Of the mutants, P21?1-35 showed a virtually identical FH binding to 
the full-length P21 (Kd ~8.4 nM), indicating that the N-terminal amino acid 
residues 1-35 of P21 are not required for FH binding (IV). Removing aa’s 1-45 
from P21-297, however, abolished binding activity present in P21?1-35, 
which confirmed our earlier hypothesis (V). This suggests that P21 aa:s 35-45 
contains crucial binding determinants (4 K residues in P21, 2 K residues in 
OspE-BITS). The mutant P21?105-166 showed no binding of FH, while the 
mutant P21?143-166 as well as the deletion mutant P21?152-166 that 
lacked only 15 C-terminal residues had only a minimal ability to bind FH.  
Next we tested, whether the shortest FH constructs with OspE binding activity 
would bind to the C-terminally truncated P21-proteins. Some binding of the 
FH constructs SCR18-20 and SCR19-20 occurred to the C-terminally 
truncated mutant P21-proteins P21?143-166 and P21?152-166, although 
the binding was significantly reduced when compared to full-length P21. This 
indicated that region V consisting of the C-terminal 15 amino acid residues is 
critical for FH binding. Importantly, however, this does not exclude the 
possibility that additional sites contribute to the binding. This is because weak 
residual binding of FH and of the huH18-20 and huH19-20 fragments was 
observed to the C-terminally truncated mutants of P21.  
8.10  FH binding by C-terminal peptides and peptide mapping 
analysis (III, IV) 
Since analysis of the deletion mutants suggested that the C-termini of OspE 
proteins are important for FH binding, we analyzed whether surface-
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associated peptides representing the C-terminus of OspE are sufficient for the 
binding. However, biotin-GABA-coupled peptides synthesized from the C-
termini of OspE paralogs OspE-297, P21-297 and ErpP-B31 did not bind FH 
in Biacore analysis. Also, soluble forms of the individual peptides did not 
inhibit the binding of FH to OspE (data not shown). This suggested that either 
the peptides did not adopt the correct conformation in solution or that the 
binding requires multiple binding sites on P21 for FH. The latter is compatible 
with the presence of a binding site in the 36-45 aa region at the N terminus of 
P21. 
Since the C-terminal OspE peptides immobilized on cellulose membranes 
bound FH, we analyzed the characteristics of FH binding to OspE by 
performing an alanine scanning analysis on peptides from all the five putative 
binding domains of OspE. To scan for potentially important amino acids of 
OspE in its interaction with FH, Ala was substituted for each amino acid of 
each of the regions I-V separately in peptides synthesized on a cellulose 
membrane. Radiolabeled FH was applied on the membrane and binding was 
detected using autoradiography. In this assay, FH bound to peptides I, III, IV 
and V. The replacement of any of the three lysines (Lys-162, -163 and -166) 
in peptide V completely abolished FH binding, indicating that these residues 
were crucial for FH binding. Similarly, the replacement of two (out of three) 
lysine residues in peptide IV (Lys-143 and -145) inhibited FH binding. Lysines 
appeared to contribute to binding also in peptide III and weakly in peptide I, 
while other amino acid replacements had no appreciable effects on FH 
binding. In conclusion, in this assay, lysine residues, particularly those close 
to the C-terminus of OspE, constituted the FH binding determinants. 
8.11  Inhibition of FH binding by heparin and by truncated 
mutants of P21 (II, IV) 
To test whether binding of FH to the Borrelia surface is dependent on charge, 
the effect of heparin on the interaction between FH/FHL-1 and Borrelia was 
investigated.  Radiolabeled FH and FHL-1 were incubated with whole Borrelia
burgdorferi s. s. bacteria and the influence of heparin on the binding was 
analyzed. At lower concentrations of below 30 ?g/ml, a small enhancing 
effect on FH binding to the spirochetes was observed. At higher heparin 
concentrations the binding of FH to Borrelia decreased. In contrast, the 
binding of FHL-1 showed only a small reduction when the heparin 
concentration increased. These results were in accordance with the fact that 
the C-terminal heparin/sialic acid -binding site of FH is involved in the 
interaction with Borrelia burgdorferi.
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Fluid-phase P21 and mutants thereof were tested for their ability to inhibit FH 
binding to surface coupled P21. For comparison, heparin was tested as a 
control. Inhibition of FH binding was seen with P21 and its N-terminal mutant 
but not with the mutants with deletions in the C-terminus. This further 
confirmed that the C-terminal binding site in P21 was the most essential one 
for FH binding. Heparin inhibited binding to FH already at an equimolar 
concentration (300 nM), which is in agreement with the ionic nature of the 
interaction between P21 and FH. On FH a heparin-binding site is located in 
SCR 20 (36). Thus, binding of heparin to SCR20 could hinder the interaction 
between SCR18-20 and FH. On the other hand, heparin could also bind to 
positively charged residues in P21.  
8.12  FH binding by B. garinii OspE-BITS and OspE-40/97 (V) 
When we compared different Borrelia strains for their resistance to serum, 
consistently with previous results, we found that B. garinii strain 50 was more 
sensitive than the other strains to complement-mediated lysis as judged from 
the final experimental time-point (17 h). However, transfecting a plasmid from 
B. burgdorferi 297 containing ospE-297 to B. garinii strain 50 (a transfected B.
garinii T50 strain) made the strain more resistant at the first two time-points of 
the experiment.  
Because of the lack of OspE-sequences from serum sensitive strains (only 
OspE-IP90 from B. garinii available from NCBI), two new sequences were 
obtained from serum sensitive B. garinii BITS and B. garinii 40/97 by 
sequencing products obtained by PCR. The sequences were compared to 
OspE-297 and P21-297. The sequence was hypothesized to contain the 
crucial N-terminal binding determinant (…SEFTVNIKNKK…). 
Sequence comparisons were carried out using the GoCore structural 
alignment tool and by comparing binding determinant -regions. The program 
predicted differences, which might cause the observed differences in serum 
resistance. We found crucial differences in the sequences of OspE-proteins 
from serum resistant and sensitive Borrelia-strains, especially near the N-
terminus. The 15 amino acids in the C-termini, which contain sequences 
crucial for FH binding (III), were found to be nearly identical in the full-length 
B. garinii 40 and B. burgdorferi s. s. N40 strains. Thus, in addition to regions 
predicted by GoCore, there are also other potentially important differences 
between B. garinii OspE-proteins and OspE-297/P21-297 near the N-
terminus.  
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Since B. garinii strains grown in vitro were sensitive to C attack, we wanted to 
analyze reasons for this, which possibly included lack of OspE genes or 
expression thereof. Alternatively the OspE proteins lacked FH-binding activity. 
To examine this possibility FH binding by OspE BITS and OspE 40/97 was 
analyzed by surface plasmon resonance. The OspE proteins were coupled to 
the chip and assayed with fluid phase FH. Interestingly, the B. garinii OspE 
proteins showed clearly less FH binding activity than P21-297.  
8.13 FH binding by neuroborreliosis-causing B. garinii strains 
Unlike B. garinii strains grown for prolonged periods in vitro, we found by 
ligand blotting that three out of four strains freshly isolated from CSF of 
patients with neuroborreliosis (LU59, LU165 and LU190) bound FH. The main 
FH-binding protein was most likely OspE. We also saw binding to an 
approximately 35-kDa protein similarly to that in study II. The control strains 
IAI and B31 showed clearly stronger binding of OspE. We further explored 
candidate proteins to find new FH–binding proteins. Based on preliminary 
data, we selected Bba68 from the B. burgdorferi s. s. 297 strain as a 
candidate protein. However, when the neuroborreliosis-causing strains were 
analyzed with a polyclonal antibody against Bba68, they were not found to 
express this protein. In summary, Borreliae bind FH with at least two families 
of FH-binding proteins (OspE- and Bba68-proteins). OspE-proteins seem to 
contribute also to the pathogenesis of B. garinii strains. 
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9 Discussion 
Lyme borreliosis occurrence has been increasing in Finland over the last 
decade in part due to increased awareness of health-care workers on the 
diagnosis. Lyme disease is the most common vector-borne infection in 
Finland and is spread by Ixodes ricinus ticks. In other parts of the world other 
ticks are important vectors. The occurrence of Lyme disease is mostly 
concentrated in coastal areas and archipelagos, but is found throughout the 
country. Early treatment with antibiotics is usually effective, whereas several 
vaccine development programs have ended in failures. Therefore, a clear 
need for more accurate knowledge on the pathogenesis of the disease 
existed, which motivated this work. Lyme disease may become a chronic 
condition with long-term effects on the life of the individual, which has raised 
also public concern about ways of prevention and treatment.  
9.1 Need for complement evasion by the Lyme disease 
spirochetes 
Lyme disease was first described in the 1970’s, when a novel juvenile 
rheumatoid arthritis-like condition was observed to occur in Lyme, 
Connecticut, USA (117). The causative microbe was soon described (1982) 
(118) and documented. The Lyme disease -causing spirochetes have since 
been found to include three genospecies, Borrelia burgdorferi s. s., Borrelia 
afzelii, and Borrelia garinii strains. These subspecies are very diverse in their 
genetic content and manifest differently during infection (119). Since all 
strains are invasive, they must be able to evade the immune system, 
including complement attack. The complement system is active in serum, in 
which cell-mediated actions of the immune system are absent and the serum 
sensitivity is variable between different B. burgdorferi subspecies (81).
Borrelia burgdorferi s. l. complex Lyme disease spirochetes are microbes that 
successfully suppress and evade the human immune system. Therefore, they 
cause persistent infections with immune-related long-term sequelae. Several 
microbes utilize FH binding in complement suppression. The aims of this 
study were to find out the whether binding of FH and its homologues is 
utilized also by B. burgdorferi strains for complement evasion, which 
molecules are associated with this mechanism, which primary structural 
determinants are essential in the tentative interaction, what homologues, if 
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any, of these proteins exist and whether these proteins are potential vaccine 
targets.  
9.2 Cofactor activity for C3b cleavage in B. burgdorferi s. s. 
strains 
It was first observed that B. burgdorferi s. s. strain cleave C3b into inactive 
iC3b fragments (I). The activity required the presence of FI, but no added FH 
was required. However, it turned out that the cofactor activity was dependent 
upon growth medium for the spirochetes. Rabbit factor H was indeed present 
in the culture medium BSK-H. Thus, the most likely explanation for the 
observation was utilization of this FH by the spirochetes.  
9.3 Serum resistant strains of B. burgdorferi bind FH 
The observation of factor H binding by Borrelia spirochetes resulted in this 
work, which comprises a description of a novel complement suppression 
mechanism. Factor H binding to B. burgdorferi was found to be due to OspE-
proteins (I, II, III) on the surfaces of B. burgdorferi spirochetes (I) and 
contribute to their virulence (IV). In addition, a 35 kDa protein was found to 
bind FHL-1 and FH. OspE proteins with comparatively low FH-binding affinity 
were later found to tentatively contribute to the virulence of B. garinii strains 
(V).  
Figure 5. The current concept of B. burgdorferi complement evasion. FH is 
bound by OspE and/or by other FH-binding proteins (II, III). Complement 
becomes inactivated on the surface of serum resistant Borrelia strains, but is 
activated normally on serum sensitive strains. By binding FH B. burgdorferi
can avoid opsonophagocytosis and complement killing. 
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9.4 FH binding is mediated by OspE-proteins 
A family of OspE-related plasmid-encoded proteins was found to bind FH with 
high affinity in the serum resistant strains of B. burgdorferi (III). The FH-
binding capacity of serum sensitive B. garinii strains was found to be limited 
compared to the serum resistant strains (V). This can be tentatively 
accounted for by the following: a) a lower affinity of OspE proteins in B. garinii
-strains for FH (V), b) lower quantity of OspE-expression on B. garinii
spirochetes, or possibly no surface expression (IP90, (120)) (V), c) better 
ability of OspE-specific antibodies to block FH binding to B. garinii OspE-
proteins in competition for binding sites. The affinities of the OspE-297- and 
P21-297-proteins for FH were approximately 10 nM, ErpA-B31- and ErpP-
B31-proteins for FH approximately 120 nM (IV). This suggests a relatively 
high affinity interaction. For B. garinii OspE an affinity of 268 nM for FH was 
recorder (V). 
The affinity of antibodies for antigens generally ranges from 10-4 M to 10-11 M
(121) and varies with antigen and phase of infection. Thus, the affinity of 
antibodies covers the range of observed OspE-FH affinities, suggesting that 
high affinity antibodies may, at least partially, block the interaction between 
OspE-proteins and FH. This is true especially regarding the OspE-proteins of 
B. garinii strains, which have a lower affinity for FH (268 nM for OspE-40/97). 
During B. burgdorferi infection in humans, a marked antibody response is 
formed against OspA, -B, and -C (55, 122). In related studies our research 
group has observed the presence of an OspE-response in a proportion of 
human patients with borreliosis (Panelius et al., unpublished). The 
immunogenicity of OspE in mice and rats has also been observed 
(unpublished). Whether these antibody responses can neutralize the virulence 
effect of OspE remains to be studied. 
9.5 OspE-proteins are encoded by plasmids 
OspE-related proteins are encoded by genes in circular plasmids (104), which 
contain more genetic material unique to Borrelia burgdorferi than the linear 
chromosome (84). This is consistent with the adaptive nature of the 
complement evasion mechanism. Stevenson et al. found Erp-proteins (OspE-
family proteins) to bind FH in various animal species that belong to the 
enzootic cycle of the B. burgdorferi spirochete (115). Recently it was reported 
that bacteriophages could transfer these mobile genetic elements between 
bacterial cells (123). Thus, the adaptive mechanism has an extra tool for 
creating diversity achieved via a form of symbiosis.  
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The genes encoding the OspE-protein family, or OspE paralogs are a subset 
of the upstream homology box (UHB) gene family, which also includes genes 
encoding OspF paralogs (120). 
9.6 Five putative FH binding regions are found in OspE-
proteins 
The putative FH-binding regions in the OspE-proteins were located by peptide 
scanning and using deletion mutants lacking binding regions in various 
combinations. P21, an OspE-homologue from the B. burgdorferi s. s. 297 
strain, was modified by constructing deletion mutants using PCR-cloning. 
Altogether, the P21-protein contained five putative FH-binding regions. One 
essential FH-binding region located within the amino acids 36-45 was in the 
N-terminus (V) and the remaining sites were closer to the C terminus of the 
primary structure of P21.  
These regions were found to have corresponding regions in OspE-proteins 
from B. garinii strains in a sequence alignment (V). When the five regions 
were reanalyzed, region II was not found to interact with FH demonstrating 
one of the limitations of the peptide scanning method. In addition the folding 
structure of the full-length protein is not taken into account when short 
peptides are analyzed. In the three-dimensional structure of the full-length 
protein the different binding regions may orient differently and/or may be 
sterically blocked from the interacting protein.  
Peptides synthesized from these five putative binding regions did not inhibit 
the interaction between FH and P21 in the fluid phase when examined in the 
Biacore. This suggested the relevance of analyzing the whole three-
dimensional structure of P21 as the individual peptides did not have sufficient 
electrostatic attraction for FH in the fluid phase. The individual binding regions 
are, therefore essential, but not sufficient for binding FH in the whole protein.  
9.7 The primary structure FH-binding regions contain 
crucial lysine-residues 
Lysine-residues in the OspE-related proteins were found to be essential for 
the FH-interaction, which involved the C-terminus of FH (SCR18-20) and the 
N- and C-termini of OspE-proteins (III, V). Positively charged lysine-residues 
form sites of electrostatic attraction between negatively charged regions in FH 
and zwitterionic OspE-proteins. The observed ability of heparin to inhibit this 
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interaction is consistent with the observed ionic nature of the interaction (III) 
and tentative dependence of the affinity of OspE for FH on the ionic strength 
of the environment (V). FH interactions with short peptides are generally 
dependent upon lysines (Jokiranta et al., unpublished). The C-termini of 
OspE-proteins are relatively conserved across strains. 
The B. garinii OspE-proteins contain only two lysines in the N-terminal 36-45 
region, where the P21-297 protein has altogether four lysine-residues. 
Lysines 38 and 42 were found to be replaced by glutamic acid and 
asparagine in the three studied B. garinii OspE-proteins. This, in conjunction 
with the crucial role of lysine-residues, is consistent with the lower FH-binding 
affinity observed for the B. garinii OspE-proteins. The ability of B. garinii
strains to cause infection despite their relative serum sensitivity may be 
related to their transient expression of FH-binding proteins and other virulence 
factors. Another contributing factor could be their ability to invade the CNS, 
where cytotoxic complement is more scarce than elsewhere in the body (124). 
9.8  OspE binding regions in FH  
Using FH-deletion constructs we mapped the OspE binding site on FH to the 
C-terminal SCR18-20 region. FH constructs containing SCR18-20 and 
SCR19-20 only were amplified from a human liver cDNA-library and PCR-
cloned into plasmid vectors. Using the expressed form of the protein it was 
found in Biacore that the binding site is contained within SCR18-20 with the 
removal of SCR18 reducing the observed Rmax. In comparison the binding 
Rmax of SCR18-20 was comparable to that of the interaction of the full length 
P21 protein with full-length FH (IV). This suggests that the binding site may be 
the only relevant region in the interaction with OspE-proteins making the 
interaction distinct from FH interactions with streptococcal M-proteins and 
Bba68. The latter proteins have been reported to bind to the SCR7 domain of 
FH. 
9.9  FHR-1 binding to OspE 
Several FH-related proteins that are found in human plasma were also tested 
to find out whether they bind to OspE. The representative FHR-protein, FHR-
1 was later observed to also bind to OspE. FHR-1 contains three domains (3-
5), which have a high degree of similarity with the FH SCR18-20 (Fig. 3). 
Therefore this observation is consistent with those made with FH-constructs. 
The physiological functions of FHR-proteins are under ongoing research and 
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as of yet unknown. Therefore, the relevance of FHR-1 binding to OspE is not 
yet known.  
9.10 Binding of mouse FH construct by OspE-related proteins 
An SCR18-20 construct from mouse FH was made similarly to the human FH 
SCR18-20 construct. We observed binding of the SCR18-20 fragment to P21 
(IV), implying that the full-length mouse FH-protein would also interact with 
P21. Therefore, the B. burgdorferi spirochetes most likely utilize this 
mechanism also in mouse and the binding sites in human and mouse FH are 
analogous. This information is important e.g. in considering murine animal 
models of Borrelia infections. 
9.11 Transfer of complement resistance to B. garinii 50 by 
transfection with ospE
To analyze whether complement resistance can be transferred with OspE and 
the complement-sensitive phenotype of B. garinii 50 changed to a 
complement-resistant one, transfection studies were carried out. A ospE-
containing plasmid with a kanamycin cassette was used to transfect a 
complement sensitive B. garinii 50 strain and the plasmid was maintained in 
the strain with kanamycin-selection until the serum sensitivity was tested and 
compared to B. garinii 50 and another control strain. The transfected strain 
(T50) expressed OspE on its surface. The functional test showed an 
increased resistance of the T50 strain to complement-mediated killing at 2 
hours (V). This suggests that the transfected plasmid did not decrease the 
viability of the T50 strain compared to the 50 strain, but increased its 
complement resistance. This is consistent with other observations and is the 
first evidence to directly show the effect of OspE on complement resistance. 
This also suggests the wider importance of this mechanism.  
Neither strain died in the experiment. We observed a form of biofilm-formation 
of large Borrelia burgdorferi bundles (see cover; unpublished), which likely 
served to protect Borrelia bacteria from complement. This may be analogous 
to attack of the complement system on tumors, where the outer cell-layers are 
attacked, but the inner layers protected (128). This mechanism has also been 
documented elsewhere (76). MMPs (68, 75, 129) enable the spirochetes to 
invade tissues and when they are able to grow into a larger population, they 
may be able to shield each other by forming a form of biofilm. Because there 
was a very large amount of bacteria, the majority of the cells were not 
attacked. In a physiological sense this may partially explain the difficulty in 
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treating persistent long-term infections. Transfecting a serum sensitive B.
garinii strain with a plasmid containing OspE from a serum resistant 297 
strain, increased the serum resistance of the B. garinii strain (V). This 
suggests that in in vitro cultured B. garinii spirochetes, the expression of 
OspE-proteins is suppressed.  
9.12 The relative roles of various FH-binding proteins 
Other authors recently presented an argument for a key role of CRASP-1, a 
25.9 kDa B. burgdorferi outer surface protein (125) in FH binding to Lyme 
disease spirochetes (126). CRASP-1 corresponds o the Bba68-family of 
proteins. The binding of the CRASP-1-protein is mediated by FH SCR7, which 
is distinct from the SCR18-20 region mediating OspE binding. Also, CRASP-1 
is encoded by lp54, a linear plasmid (126). The CRASP-1 protein probably 
corresponds to the 35 kDa FH-binding proteins found in study I. In addition, 
FH binding was seen to a factor H-binding protein, which most likely is OspE 
(V) in the CNS-infective B. garinii strains. The relative roles of these and 
possible other FH-binding proteins (125) remain to be elucidated. However, 
the temporal division of expression is likely the key to their central functions, 
with OspE-family proteins being expressed in a wide variety of hosts. One of 
the key differences between the Bba68- and OspE-proteins may be related to 
the relative mobility of the latter (123). 
9.13 The expression of FH-binding proteins is regulated by 
external factors 
This work has pinpointed crucial virulence proteins and primary structures, 
whose expression is regulated by external factors. It was observed that OspE-
expression is upregulated upon temperature change from 22°C to 37°C (III). 
Mammalian-specific expression of OspE-proteins has been reported also 
elsewhere (101, 103, 127). Future studies on the relative roles and ubiquity of 
OspE-proteins and other FH-binding proteins in B. burgdorferi and other 
pathogenic microbes will shed more light into the importance of this 
mechanism at the interface between the human immune system and 
pathogens.  
The temporally controlled expression of virulence factors may also explain the 
virulence of B. garinii strains in infecting the CNS. It was observed that B. 
garinii strains have a higher sensitivity to complement in vitro compared to B. 
burgdorferi s. s. and B. afzelii strains. Nevertheless, they seem to enter the 
CNS where they can escape complement, which is relatively scarce inside the 
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CNS. This may require the temporally regulated expression of virulence 
factors, such as OspE or Bba68-proteins or other FH-binding proteins 
preceding entry. As observed in study V, the OspE proteins are expressed in 
B. garinii strains freshly isolated from the CNS. 
9.14 Key mechanisms of pathogenesis and future studies 
This work has answered some of the most central questions in Lyme disease 
pathogenesis. Apparently, the utilization of the FH-binding proteins, which 
include the OspE, and Bba68 families of proteins are important to the 
virulence of Borrelia burgdorferi spirochetes. A rigorous proof for this 
necessitates animal model studies. The generation of e.g. OspE-transfected 
strains of B. garinii and other analogous gene-manipulated Borreliae will be 
instrumental for studies of this kind.  
At least two proteins (130, 131) have been studied as vaccine candidates 
against Lyme disease. A vaccine using OspA as antigen was sold for some 
time in North America, but it was withdrawn because of arthritogenic side-
effects (132). Subsequently, the vaccine was redesigned to contain a 
recombinant antigen lacking a potentially cross-reactive site (58) and currently 
exists as a second-generation rOspA vaccine (133). However, similarly to the 
first-generation OspA vaccine, the rOspA vaccine is only effective against 
North-American strains. In the Åland islands, Finland, a polyvalent vaccine 
(134), utilizing the OspC antigen (135) was undergoing clinical testing but this 
testing has been discontinued. Therefore, no currently available vaccine 
exists for the European market.  
Computer prediction studies indicate that OspE has an overall coiled-coil-type 
structure. In this regard, it resembles other FH-binding proteins, e.g. M-protein 
of group A streptococci (136) and PspC-family proteins of pneumococci (41).  
Future studies regarding the three-dimensional structure of OspE and Bba68-
family proteins would be of potential interest for docking analysis of the FH-
OspE interaction, which would enable the design of targeted antigen design 
for vaccines and/or pharmacotherapy.  
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10 Conclusions 
This work has demonstrated that Lyme disease spirochetes utilize FH binding 
as a complement evasion mechanism. The complement inhibitor factor H 
binds with its C terminus to plasmid-encoded OspE surface proteins of B.
burgdorferi. The OspE-family of FH-binding proteins, therefore, constitutes a 
family of virulence factors, which affect the complement sensitivity of B.
burgdorferi s. l. spirochetes. In addition, another FH-binding protein family 
was observed and identified by others as the Bba68-family of proteins. This 
information may enable the development of new, effective vaccines against a 
wide range of strains 
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